Aceclidine Eye Drops (Aceclidine) is a novel cholinergic agonist first approved in the United States in 2025, specifically indicated for the treatment of presbyopia in adults. As a prescription medication, a comprehensive understanding of its side effect profile, risks of serious adverse reactions, and usage precautions is crucial for medication safety and therapeutic efficacy.
Side Effects of Aceclidine Eye Drops (Aceclidine)
Local Irritant Reactions
Instillation site irritation: 20%.
Dim vision: 16%.
Headache: 13%.
Other adverse reactions with an incidence rate above 5% include conjunctival hyperemia (8%) and ocular hyperemia (7%).
Transient Effects on Visual Function
Temporary changes in visual function may occur after drug administration, mainly manifested as blurred vision and dimness.
Such reactions stem from the drug's impact on the eye's accommodation mechanism, typically being most pronounced within a period after administration and then gradually subsiding.
Patients need to pay special attention to avoiding driving or operating machinery when vision is unclear, and exercise extreme caution when engaging in hazardous activities such as night driving or working in poorly lit environments.
Serious Side Effects of Aceclidine Eye Drops (Aceclidine)
Risk of Retinal Complications
As a miotic, aceclidine has been rarely reported to cause serious adverse reactions such as retinal tears and retinal detachment in susceptible individuals and patients with pre-existing retinal lesions.
Although the incidence of such complications is low, the consequences are severe and may result in permanent visual impairment.
A baseline retinal examination is recommended for all patients before initiating treatment.
Warning signs include sudden onset of photopsia, floaters, or vision loss.
Once these symptoms appear, patients should seek immediate professional medical assistance for timely diagnosis and intervention.
Risk of Exacerbated Ocular Inflammation
For patients with a history of iritis, the use of miotics may exacerbate ocular inflammatory sequelae, particularly the formation of adhesions between the iris and lens (posterior synechiae).
Such patients must use the drug under close medical monitoring, with a full weighing of the therapeutic benefits against potential risks.
Possibility of Allergic Reactions
The drug is not recommended for patients with known hypersensitivity to aceclidine or any component of Aceclidine Eye Drops.
In clinical practice, detailed inquiries should be made about the patient’s drug allergy history, especially previous adverse reactions to ophthalmic medications.
Precautions for Aceclidine Eye Drops (Aceclidine)
Correct Administration Method
The recommended dosage of Aceclidine Eye Drops is one drop per eye, once daily.
After waiting for 2 minutes, instill a second drop into the same eye using the same single-dose vial.
Contact Lens Usage Guidelines
Contact lenses should be removed before instilling aceclidine, and can be reinserted 10 minutes after instillation.
This time interval is established based on the absorption and distribution characteristics of the drug in the eye, which can effectively reduce interactions between the drug and lens materials.
Combined Medication Management
If the patient is using multiple topical ophthalmic medications, an interval of at least 5 minutes should be maintained between the administration of different products.
This sequential administration method avoids physical interactions between drugs and ensures the adequate absorption and efficacy of each medication.
Storage and Handling Key Points
Storage conditions: The drug must be stored refrigerated at 2°C to 8°C, and freezing should be avoided.
Room temperature use: Once removed from refrigeration, it can be stored at room temperature (maximum 25°C) but must be used within 30 days.
To prevent ocular injury or contamination, care should be taken to avoid contact between the single-dose vial and the eye or any other surface during use.
Opened single-dose vials should be discarded immediately after use and must not be reused.
